For patients & Public

According to the World Health Organisation (WHO), Cardiometabolic diseases (CMDs) are the number-one cause of death in the world.

ADHD is one of the most common neurodevelopmental conditions not only of childhood, as is often assumed by the public, but also one that can last into adulthood, affecting between 3% and 5% of adults worldwide.

ADHD often co-occurs with other health conditions, including cardiometabolic diseases, mood and anxiety disorders, and substance use challenges. These combinations can lead to more frequent use of healthcare services, not because people with ADHD are inherently “costly”, but because their needs often go unmet for too long. Studies have shown that when co-occurring conditions are not addressed early, healthcare costs increase over time¹.

TIMESPAN is working to better understand these links and ensure that people with ADHD receive earlier, more coordinated care that supports their overall wellbeing.

—

(1)

Hodgkins P et al. (2011). Cost of illness and comorbidities in adults diagnosed with attention-deficit/hyperactivity disorder: a retrospective analysis. Prim Care Companion CNS Disord, 13(2): PCC.10m01030

Libutzki B et al. (2019). Direct medical costs of ADHD and its comorbid conditions on basis of a claims data analysis. European Psychiatr: the journal of the Association of European Psychiatrists, 58: pp. 38-44

Du Rietz E et al. (2020). Trajectories of healthcare utilization and costs of psychiatric and somatic multimorbidity in adults with childhood ADHD: a prospective register-based study. J Child Psychol Psychiatry, 61(9): pp. 959-968